Daniel F. Hayes
Daniel F. Hayes
professor internal medicine
Verified email at umich.edu
Title
Cited by
Cited by
Year
College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer
AC Wolff, ME Hammond, JN Schwartz, KL Hagerty, DC Allred, RJ Cote, ...
J clin oncol 25 (1), 118-145, 2007
49392007
Circulating tumor cells, disease progression, and survival in metastatic breast cancer
M Cristofanilli, GT Budd, MJ Ellis, A Stopeck, J Matera, MC Miller, ...
New England Journal of Medicine 351 (8), 781-791, 2004
42132004
ALDH1 is a marker of normal and malignant human mammary stem cells and a predictor of poor clinical outcome
C Ginestier, MH Hur, E Charafe-Jauffret, F Monville, J Dutcher, M Brown, ...
Cell stem cell 1 (5), 555-567, 2007
39092007
College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer
ME Hammond, DF Hayes, M Dowsett, DC Allred, KL Hagerty, S Badve, ...
J Clin Oncol 28 (16), 2784-2795, 2010
37262010
Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice …
AC Wolff, MEH Hammond, DG Hicks, M Dowsett, LM McShane, ...
Archives of Pathology and Laboratory Medicine 138 (2), 241-256, 2014
35262014
American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer
AC Wolff, MEH Hammond, JN Schwartz, KL Hagerty, DC Allred, RJ Cote, ...
Archives of pathology & laboratory medicine 131 (1), 18-43, 2007
33032007
American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in …
MEH Hammond, DF Hayes, M Dowsett, DC Allred, KL Hagerty, S Badve, ...
Archives of pathology & laboratory medicine 134 (7), e48-e72, 2010
27032010
American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer
L Harris, H Fritsche, R Mennel, L Norton, P Ravdin, S Taube, ...
Journal of clinical oncology 25 (33), 5287-5312, 2007
26102007
Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013
A Goldhirsch, EP Winer, AS Coates, RD Gelber, M Piccart-Gebhart, ...
Annals of oncology 24 (9), 2206-2223, 2013
26072013
EZH2 is a marker of aggressive breast cancer and promotes neoplastic transformation of breast epithelial cells
CG Kleer, Q Cao, S Varambally, R Shen, I Ota, SA Tomlins, D Ghosh, ...
Proceedings of the National Academy of Sciences 100 (20), 11606-11611, 2003
16392003
Prognostic factors in breast cancer: College of American Pathologists consensus statement 1999
PL Fitzgibbons, DL Page, D Weaver, AD Thor, DC Allred, GM Clark, ...
Archives of pathology & laboratory medicine 124 (7), 966-978, 2000
15572000
ASCO 2006 update of recommendations for the use of tumor markers in gastrointestinal cancer
GY Locker, S Hamilton, J Harris, JM Jessup, N Kemeny, JS Macdonald, ...
Journal of clinical oncology 24 (33), 5313-5327, 2006
15492006
Revision of the American Joint Committee on Cancer staging system for breast cancer
SE Singletary, C Allred, P Ashley, LW Bassett, D Berry, KI Bland, ...
Journal of clinical oncology 20 (17), 3628-3636, 2002
15412002
Improved outcomes from adding sequential paclitaxel but not from escalating doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast …
IC Henderson, DA Berry, GD Demetri, CT Cirrincione, LJ Goldstein, ...
Journal of clinical oncology 21 (6), 976-983, 2003
15352003
A second generation of multivariate analysis. 2. Measurement and evaluation
C Fornell
Praeger Publishers, 1982
1445*1982
Tailoring therapies—improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015
AS Coates, EP Winer, A Goldhirsch, RD Gelber, M Gnant, ...
Annals of oncology 26 (8), 1533-1546, 2015
14242015
Assessment of Ki67 in breast cancer: recommendations from the International Ki67 in Breast Cancer working group
M Dowsett, TO Nielsen, R A’Hern, J Bartlett, RC Coombes, J Cuzick, ...
Journal of the National cancer Institute 103 (22), 1656-1664, 2011
14032011
Phase II study of receptor-enhanced chemosensitivity using recombinant humanized anti-p185HER2/neu monoclonal antibody plus cisplatin in patients with HER2/neu-overexpressing …
MD Pegram, A Lipton, DF Hayes, BL Weber, JM Baselga, D Tripathy, ...
Journal of clinical oncology 16 (8), 2659-2671, 1998
13171998
American Society of Clinical Oncology Provisional Clinical Opinion: Testing for KRAS Gene Mutations in Patients With Metastatic Colorectal Carcinoma to Predict …
CJ Allegra, JM Jessup, MR Somerfield, SR Hamilton, EH Hammond, ...
Journal of clinical oncology 27 (12), 2091-2096, 2009
13002009
Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy: a …
KS Albain, WE Barlow, S Shak, GN Hortobagyi, RB Livingston, IT Yeh, ...
The lancet oncology 11 (1), 55-65, 2010
12382010
The system can't perform the operation now. Try again later.
Articles 1–20